Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Drug discovery and development

Experimental diabetes drug shows promise in Parkinson’s disease

The drug, MSDC-0160, offers a new approach to treating Parkinson’s disease, targeting the underlying disease rather than alleviating symptoms.

Parkinson’s disease in MRI brain scan

Source: Shutterstock

An experimental diabetes drug may have potential to treat Parkinson’s disease (MRI scan pictured), targeting the underlying disease

An experimental drug originally developed for type 2 diabetes has shown early promise as a treatment for Parkinson’s disease, say researchers who are now planning a clinical trial in humans.

Known as MSDC-0160, the drug differs from current treatments for Parkinson’s disease in that rather than simply alleviating symptoms, it is designed to target the underlying disease.

Study leader Patrik Brundin, director of the Van Andel Research Institute’s Center for Neurodegenerative Science, Michigan, hopes the study will be a “watershed moment” for Parkinson’s disease research.

“All of our research in Parkinson’s models suggests this drug could potentially slow the disease’s progression in people as well,” he says.

He adds that, if successful in human trials, MSDC-0160 would be the first therapy in Parkinson’s disease to treat the underlying disease and potentially slow its progression.

Several studies have shown potential similarities in metabolic changes at the molecular level in diabetes and Parkinson’s disease. This has led to an increased interest in the effects of thiazolidinediones – a group of insulin sensitising drugs – in patients with Parkinson’s disease, the US researchers report in Science Translational Medicine[1] (online, 7 December 2016).

In the latest study, the researchers tested MSDC-0160 — developed to act in a similar way to thiazolidinediones but with fewer side effects — in several animal and cell models of Parkinson’s disease.

The laboratory experiments suggested that the new drug, which targets a transport protein in mitochondria, regulates mitochondrial function in brain cells and restores the cells’ ability to convert basic nutrients into energy. This led to reduced levels of inflammation and less nerve cell death in several different Parkinson’s models tested.

In mice genetically engineered to mimic Parkinson’s disease, long-term use of MSDC-0160 was found to preserve motor function and reduce neuroinflammation.

Tom Isaacs, a co-founder of The Cure Parkinson’s Trust, a charity based in London, which part-funded the study, says: “Our scientific team has evaluated more than 120 potential treatments for Parkinson’s disease, and MSDC-0160 offers the genuine prospect of being a breakthrough that could make a significant and permanent impact on people’s lives in the near future.” He says they are working to move the drug into clinical trials as quickly as possible and hope to start in 2017.

Claire Bale, head of research communications and engagement at Parkinson’s UK, a charity based in London, says to date no treatment had been found that can either stop or slow down the advancement of Parkinson’s.

“Although it has so far only been tested in mice models, the MSDC-0160 drug shows significant promise; indicating improvements in motor function, maintaining dopamine production and protecting the cells lost in a number of models of the condition,” she says.

“While other diabetes drugs have shown promise in Parkinson’s, they can have serious side effects.

“Encouragingly, this new drug appears to have a better safety profile, which we hope will translate into good long-term safety in people with the condition.”

Bale adds that it is essential that clinical trials are geared towards people in the early stages of the disease where the protective properties of the drug are likely to have the greatest impact.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2016.20202062

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Drugs of Abuse

    Drugs of Abuse

    A concise, easy-to-read guide for healthcare professionals who encounter drug abuse.

    £38.00Buy now
  • Pharmaceutical Toxicology

    Pharmaceutical Toxicology

    Explains the methodology and requirements of pre-clinical safety assessments of new medicines. Includes registration requirements and pharmacovigilance.

    £40.00Buy now
  • Adverse Drug Reactions

    Adverse Drug Reactions

    A practical guide to the drug reactions that affect particular organ systems, and the management of these reactions.

    £38.00Buy now
  • English Delftware Drug Jars

    English Delftware Drug Jars

    This beautiful book illustrates the art and history of the collection of English delftware drug jars in the Museum of the Royal Pharmaceutical Society of Great Britain.

    £54.00Buy now
  • Paediatric Drug Handling

    Paediatric Drug Handling

    Written for new pharmaceutical scientists, this book provides a background in paediatric pharmacy and a comprehensive introduction to children's medication.

    £33.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Parkinson’s disease in MRI brain scan

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.